Eli Lilly and Company $LLY Shares Sold by Allspring Global Investments Holdings LLC

Key Points

• Allspring Global Investments Holdings LLC reduced its stake in Eli Lilly by 1.6%, now owning 121,678 shares valued at approximately $94.41 million.
• Eli Lilly reported strong quarterly earnings with $6.31 earnings per share, significantly exceeding analysts' expectations of $5.59.
• Insider activity included Director Jamere Jackson purchasing 200 shares at an average price of $639.56, increasing their holdings in the company.

Allspring Global Investments Holdings LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 121,678 shares of the company's stock after selling 1,977 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in Eli Lilly and Company were worth $94,410,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Index Fund Advisors Inc. boosted its holdings in Eli Lilly and Company by 159.7% in the 2nd quarter. Index Fund Advisors Inc. now owns 1,218 shares of the company's stock valued at $950,000 after purchasing an additional 749 shares during the last quarter. M3 Advisory Group LLC boosted its holdings in Eli Lilly and Company by 5.0% in the 2nd quarter. M3 Advisory Group LLC now owns 636 shares of the company's stock valued at $496,000 after purchasing an additional 30 shares during the last quarter. Yarger Wealth Strategies LLC boosted its holdings in Eli Lilly and Company by 24.1% in the 2nd quarter. Yarger Wealth Strategies LLC now owns 577 shares of the company's stock valued at $450,000 after purchasing an additional 112 shares during the last quarter. Sharp Financial Services LLC boosted its holdings in Eli Lilly and Company by 13.1% in the 2nd quarter. Sharp Financial Services LLC now owns 431 shares of the company's stock valued at $336,000 after purchasing an additional 50 shares during the last quarter. Finally, Mitchell Sinkler & Starr PA boosted its holdings in Eli Lilly and Company by 1.2% in the 2nd quarter. Mitchell Sinkler & Starr PA now owns 2,431 shares of the company's stock valued at $1,895,000 after purchasing an additional 30 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 1.8%

Shares of LLY stock opened at $818.60 on Tuesday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market capitalization of $774.77 billion, a P/E ratio of 53.50, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. The company has a 50 day moving average price of $743.43 and a 200 day moving average price of $765.54. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, Director Jamere Jackson purchased 200 shares of the stock in a transaction on Friday, August 8th. The stock was bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director directly owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock worth $2,894,841 over the last ninety days. 0.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on LLY shares. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. HSBC boosted their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Berenberg Bank reissued a "hold" rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Finally, Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $948.06.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.